The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers.

Benatar M (speaker). The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers. ALS One 5th Annual ALS Research Symposium. Virtual, Oct 6-7, 2022.